05:17 AM EST, 12/10/2024 (MT Newswires) -- Legend Biotech ( LEGN ) disclosed late Monday new results from a phase 3 study showing a single infusion of Carvykti provided "significantly higher" rates of minimal residual disease-negativity in patients with relapsed or lenalidomide-refractory multiple myeloma.

The medication is for patients who have received at least one prior line of therapy, including a proteasome inhibitor and an immunomodulatory agent.

The company said that 89% of evaluable patients achieved minimal residual disease negativity with Carvykti after a three-year follow-up in the study, with the "majority in less than 2 months." The results "add" to the overall survival benefit recently reported.

"The latest MRD data showcases the advances of Carvykti and further demonstrates why it is a leading treatment for patients with multiple myeloma," said Ying Huang, chief executive officer of Legend Biotech ( LEGN ).